SRR12696775
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.300
- PROTEIN_SECRETION+0.300
- APICAL_SURFACE+0.200
- MTORC1_SIGNALING+0.200
- MYC_TARGETS_V1+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- PANCREAS_BETA_CELLS+0.200
- SPERMATOGENESIS+0.200
- CHOLESTEROL_HOMEOSTASIS+0.100
- DNA_REPAIR+0.100
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- MYOGENESIS-0.400
- APICAL_JUNCTION-0.300
- COAGULATION-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- TGF_BETA_SIGNALING-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10900014 | — | — | 0.828 |
| 2 | TCGA-CV-A45Z-01A-21R-A24Z-07 | — | — | 0.823 |
| 3 | TCGA-QK-A8ZA-01A-11R-A39I-07 | — | — | 0.821 |
| 4 | s0095168 | — | — | 0.808 |
| 5 | R130 | — | — | 0.802 |
| 6 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.794 |
| 7 | SRR26320088 | — | — | 0.793 |
| 8 | R55 | — | — | 0.792 |
| 9 | 513fb61a-1339-45d2-8963-6337e3aff5df | — | — | 0.790 |
| 10 | AUR-AFR4-TTM1-A-1-1-R-A743-41 | — | E | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |